The Conversation (0)
OncBioMune Pharmaceuticals kicked off its formulation working with tretinoin in order to treat Acute Promyelocytic Leukemia.
OncBioMune Pharmaceuticals (OTCQB:OBMP) kicked off its formulation working with tretinoin in order to treat Acute Promyelocytic Leukemia.
As quoted in the press release:
Tretinoin is an oral drug for the treatment of Acute Promyelocytic Leukemia (APL). OncBioMune has acquired commercialization rights for tretinoin throughout Mexico, Central America and Latin America from the leading South American CMO.
There is no approved product in Mexico for the treatment of APL, an aggressive type of acute myeloid leukemia. As such, OncBioMune feels it is positioned to emerge as a market leader for the indication with tretinoin.
Formulation work will be followed by stability studies, with expectations for commercialization of tretinoin under the OncBioMune brand across Mexico, Central America and Latin America in 2018.
Click here to read the full press release.
Source: www.marketwired.com
